Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
                
Learn More
Learn More
                                    TRIM21/SSA1 Antibody, Novus Biologicals™
                                    
                                    
                                    
                                    
                                
                            
                            
                            
                            
Rabbit Polyclonal Antibody
Supplier: Novus Biologicals NBP137009
Description
TRIM21/SSA1 Polyclonal specifically detects TRIM21/SSA1 in Human samples. It is validated for Immunoprecipitation, Western Blot (Negative).Specifications
| TRIM21/SSA1 | |
| Polyclonal | |
| Unconjugated | |
| Tris-Citrate/Phosphate (pH 7.0 - 8.0) with 0.09% Sodium Azide | |
| TRIM21 | |
| The immunogen for this product maps to a region between residue 250 and 300 of human Sjogren syndrome antigen A1 using the numbering given in entry NP_003132.2 (GeneID 6737). | |
| 100 μL | |
| Primary | |
| Human | |
| IgG | 
| Immunoprecipitation, Western Blot | |
| 1.0 mg/mL | |
| Immunoprecipitation 5-15 ug/mg lysate, Western Blot (Negative) | |
| 52 kDa ribonucleoprotein autoantigen Ro/SS-A, 52 kDa Ro/SSA, E3 ubiquitin-protein ligase TRIM21, EC 6.3.2.-, rhTRIM21, RNF81RING finger protein 81, ro(SS-A), RO52SS-A, Sicca syndrome antigen A, Sjoegren syndrome type A antigen, Sjogren syndrome antigen A1 (52kDa, ribonucleoprotein autoantigen SS-A/Ro), SSA1SSA, tripartite motif containing 21,52 kDa Ro protein, tripartite motif-containing 21, Tripartite motif-containing protein 21 | |
| Rabbit | |
| Affinity Purified | |
| RUO | |
| 6737 | |
| Store at 4C. Do not freeze. | 
                    Product Content Correction
                
                Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
			
            For Research Use Only
Spot an opportunity for improvement?Share a Content Correction